Items Tagged ‘Pamrevlumab. FG-3019’

March 2nd, 2017

Preliminary Results Suggest That Pamrevlumab is Promising in Pancreatic Cancer

By

Updated results from an ongoing clinical study of pamrevlumab (FG-3019) in combination with standard-of-care chemotherapy in patients with locally advanced pancreatic ductal adenocarcinoma were presented during the ASCO 2017 Gastrointestinal Cancers Symposium in San Francisco and appear to suggest pamrevulmab may improve outcomes compared to chemotherapy alone. About Pancreatic Ductal Adenocarcinoma and Connective Tissue Growth […]

View full entry

Tags: connective tissue growth factor, News, Pamrevlumab. FG-3019, Pancreatic Cancer